Article > Actelion partners with PatientsLikeMe in research initiative

"PatientsLikeMe and Actelion have hooked up under a new research initiative to create a new patient-reported outcomes tool for the rare form of non-Hodgkin's lymphoma called MF-CTCL.    The alliance intends to leverage the patient network’s Open Research Exchange (ORE) - an online hub for developing and sharing new health measures that better reflect patients’ experiences in living with and managing disease, which researchers can use in the design of clinical trials, for example.   Actelion is the first pharmaceutical company to use ORE to create a measure for a rare condition and, once completed, to share it with other researchers, the firms said ..."